13F Holdings
中文EN

AWHL Aspira Women's Health Inc.

In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 926617 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY112.2%
TTM net income YoY55.8%
TTM EPS YoY71.4%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—

Margins

Gross margin1,481.2%
Operating margin-2,079.9%
Net margin-1,520.4%
FCF margin—
EBITDA margin-2,026.1%

Returns

ROE—
ROA-87.8%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets291.9%
Debt / equity—
Current ratio0.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.08x
Accruals ratio6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$343,000$4,000$87.00M$8.18M$6.81M
Cost of revenue$3.30M$3.70M$3.89M$3.86M$3.75M
Gross profit$5.92M$5.48M$5.26M$4.32M$3.06M
R&D expense$2.88M$3.27M$4.04M$5.92M$5.31M
SG&A expense$7.96M$10.35M$12.27M$14.63M$13.26M
Operating income-$7.91M-$16.28M-$18.85M-$31.14M-$32.59M
Pretax income-$12.78M-$13.09M$16.69M$29.90M$31.66M
Net income-$12.78M-$13.09M-$16.69M-$29.89M-$31.66M
EBITDA-$7.80M-$16.19M-$18.65M-$30.87M-$32.29M
EPS (basic)-0.37-0.93-1.81-3.85-4.27
EPS (diluted)-0.37-0.93-1.81-3.85-4.27
Weighted avg. shares (diluted)34.10M14.13M9.23M7.77M7.41M
Banking
Net interest income-$41,000-$33,000$48,000$17,000-$48,000
Balance sheet
Cash & equivalents$1.75M$1.77M$2.60M$13.56M$37.43M
Receivables$1.21M$990,000$1.46M$1.25M$1.03M
Inventory$256,000$326,000$227,000$316,000$174,000
Current assets$4.06M$4.18M$5.28M$16.31M$40.01M
PP&E, net$47,000$69,000$165,000$368,000$464,000
Intangibles$310,000————
Total assets$5.46M$5.49M$6.26M$17.37M$41.08M
Current liabilities$3.46M$5.47M$5.12M$5.53M$7.84M
Short-term debt$236,000$229,000$166,000$403,000$201,000
Long-term debt$1.04M$1.28M$1.43M$2.31M$2.72M
Total debt$1.28M$1.51M$1.60M$2.72M$2.92M
Total liabilities$12.39M$8.05M$8.63M$10.39M$10.91M
Shareholders' equity-$6.93M-$2.56M-$2.37M$6.98M$30.17M
Net debt-$478,000-$262,000-$1.00M-$10.84M-$34.51M
Shares outstanding43.48M17.41M10.65M8.31M7.48M
Cash flow statement
Operating cash flow-$7.03M-$12.11M-$15.89M-$31.07M-$27.39M
Capital expenditure$16,000$37,000$24,000$232,000$184,000
Free cash flow-$7.04M-$12.15M-$15.92M-$31.30M-$27.58M
Investing cash flow-$401,000-$37,000-$24,000-$232,000-$184,000
Financing cash flow$7.42M$11.06M$5.22M$7.43M$48.38M
Depreciation & amortization$112,000$92,000$199,000$264,000$302,000
Stock-based compensation$531,000$1.49M$1.72M$2.41M$3.54M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.